ClinicalTrials.gg
CompletedNCT01215318Updated Aug 28, 2019Results posted

FDG Uptake in Vaginal Tampons is Due to Urine

An interventional study of modified vaginal tampon in Cancer, sponsored by Irene Burger. Completed at 1 site in Switzerland. Open to female participants aged 20 Years to 48 Years. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Irene Burger · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2010, registered Oct 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years to 48 Years
Sex
Female
01

Study summary

The etiology of FDG uptake in vaginal tampons during PET/CT examinations remains unclear and can potentially impair image interpretation.

The aim of this study is to determine the etiology of this artefact and identify potential means how to prevent it.

Read the detailed description

In this prospective, Institutional Review board approved study we included 44 women referred to FDG PET/CT for staging or follow-up in an oncology setting. All women were provided a normal commercial or modified vaginal tampon with a silicon coated base to be used during examination. Images were analyzed to determine the localization and the FDG uptake in the tampons. Between the uptake phase and imaging, all patients were asked to void. After image acquisition, tampons were individually analyzed for creatinine concentration, blood traces, position relative to the pubococcygeal line, and FDG activity. Statistical significance was determined by means of the Mann-Whitney U test.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • FDG PET/CT, vaginal tampon, urinary contamination, pitfall
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 44 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Irene Burger is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 48 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria: premenopausal women with known or suspected who regularly used vaginal tampons during menstruation and thus were familiar with their use

Exclusion criteria: No cervical or genital carcinoma. No vaginal infection.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Modified vaginal tampons

    Patients using modified vaginal tampons during FDG PET/CT

    Device: modified vaginal tampon

  • Placebo comparator
    Unmodified vaginal tampons

    Patients using unmodified vaginal tampons during FDG PET/CT

    Device: modified vaginal tampon

Interventions

  • Devicemodified vaginal tampon

    modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination

    Also known as: Ob® Regular; Johnson & Johnson, with silicon seal

06

What researchers measure

Primary outcomes

  1. Number of FDG Positive Tampoons

    Number of FDG positive Tampoons with an SUV \> 3

    Time frame: 1 month

Secondary outcomes

  1. Tampon Position Relative to the Pubococcygeal Line

    measure tampon position in regard to the pubococcygeal line to identify if positioning is responsible for urinary contamination.

    Time frame: 1 month

07

Results

Posted Aug 28, 2019
Limitations and caveats
absence of gynecological examination. Vaginal tampon position was only assessed with respect to the pubococcygeal line visualized on computer tomography.

Participant flow

Premenopausal women referred for FDG PET/CT examination for staging or follow up of malign disease, were given a modified or unmodified vaginal tampon during the PET/CT examination.

Participant flow — Overall Study
MilestoneModified Vaginal TamponsUnmodified Vaginal Tampons
Started2024
Completed2024
Not completed00

Outcome measures

PrimaryNumber of FDG Positive Tampoons

Number of FDG positive Tampoons with an SUV \> 3

Time frame:
1 month
Reported as:
Number · FDG positive tampons
Number of FDG Positive Tampoons
FDG positive tamponsModified Vaginal TamponsUnmodified Vaginal Tampons
Number of FDG Positive Tampoons210
SecondaryTampon Position Relative to the Pubococcygeal Line

measure tampon position in regard to the pubococcygeal line to identify if positioning is responsible for urinary contamination.

Time frame:
1 month
Reported as:
Mean · mm
Tampon Position Relative to the Pubococcygeal Line
mmModified Vaginal TamponsUnmodified Vaginal Tampons
Tampon Position Relative to the Pubococcygeal Line5.9 ± 175.1 ± 11

Adverse events

Collected over During FDG PET/CT scan (2 hours). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Modified Vaginal Tampons—0/20 (0%)0/20 (0%)
Unmodified Vaginal Tampons—0/24 (0%)0/24 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Modified Vaginal TamponsUnmodified Vaginal TamponsTotal
<=18 years000
Between 18 and 65 years202444
>=65 years000
Age, Continuous
Age, Continuous(years)Modified Vaginal TamponsUnmodified Vaginal TamponsTotal
Mean39 ± 7.737 ± 8.439 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Modified Vaginal TamponsUnmodified Vaginal TamponsTotal
Female202444
Male000
Region of Enrollment
Region of Enrollment(participants)Modified Vaginal TamponsUnmodified Vaginal TamponsTotal
Switzerland202444
08

Study locations

1 site
  • University Hospital Zurich
    Zurich, 8091, Switzerland
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Aug 2010, 6 months.

Results were first posted in Aug 2019, 9 years after primary completion.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 6 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2010
First posted
Oct 6, 2010
StartActual
Feb 2, 2010
Primary completionActual
Aug 2, 2010
CompletionActual
Sep 30, 2010
Results first posted
Aug 28, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01215318
Lead sponsor
Irene Burger
Responsible party
Irene Burger (Attending physician, University of Zurich) — Sponsor-investigator
First posted
Oct 6, 2010
Start date
Feb 2, 2010
Primary completion
Aug 2, 2010
Completion
Sep 30, 2010
Results posted
Aug 28, 2019
Last update
Aug 28, 2019

Study contacts

01 Studienregister MasterAdmins
study director · UniversitaetsSpital Zuerich

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion